MARKETS
PERPS
LIVE
49
PRO
NEW
MORE
Cash
Portfolio
Log in
Sign up
Trending
Elections
Politics
Culture
Sports
Crypto
Commodities
Climate
Economics
Mentions
Finance
Tech & Science
Predict
Live
49
Account
Search
Social
Trending
Elections
Politics
Culture
Sports
Crypto
Commodities
Climate
Economics
Mentions
Finance
Tech & Science
Medtronic
MDT
Earnings Call
Reports
Sep 1, 2026 · before open
Fiscal period
Not stated
Market cap
$115.95B
Consensus EPS
$1.38 · 8 estimates
Year-ago EPS
$1.26
Expected change
+9.5%
Quarterly markets
Q1 Cardiovascular Organic Revenue Growth
Open interest
4,450
Volume
4.45K
Trade
Q4 2026 reported
10.1%
-4.7% QoQ
Reported
Other figures MDT reports
26 more reported metrics with no market on them yet
Acute Care & Monitoring Revenue
Cardiac Rhythm & Heart Failure Revenue
Cardiovascular Operating Profit
Cardiovascular Revenue
Coronary & Peripheral Vascular Revenue
Cranial & Spinal Technologies Revenue
Diabetes Operating Profit
Diabetes Organic Revenue Growth
Diabetes Revenue
Emerging Markets Revenue
Medical Surgical Operating Profit
Medical Surgical Organic Revenue Growth
Medical Surgical Revenue
Neuromodulation Revenue
Neuroscience Operating Profit
Neuroscience Organic Revenue Growth
Neuroscience Revenue
Non-U.S. Developed Markets Revenue
Other Segment Operating Profit
Other Segment Revenue
Specialty Therapies Revenue
Structural Heart & Aortic Revenue
Surgical & Endoscopy Revenue
Total International Revenue
Total Organic Revenue Growth
U.S. Revenue
Acute Care & Monitoring Revenue
Cardiac Rhythm & Heart Failure Revenue
Cardiovascular Operating Profit
Cardiovascular Revenue
Coronary & Peripheral Vascular Revenue
Cranial & Spinal Technologies Revenue
Diabetes Operating Profit
Diabetes Organic Revenue Growth
Diabetes Revenue
Emerging Markets Revenue
Medical Surgical Operating Profit
Medical Surgical Organic Revenue Growth
Medical Surgical Revenue
Neuromodulation Revenue
Neuroscience Operating Profit
Neuroscience Organic Revenue Growth
Neuroscience Revenue
Non-U.S. Developed Markets Revenue
Other Segment Operating Profit
Other Segment Revenue
Specialty Therapies Revenue
Structural Heart & Aortic Revenue
Surgical & Endoscopy Revenue
Total International Revenue
Total Organic Revenue Growth
U.S. Revenue
Q4 2026 reported
$568,000,000
+9.4% QoQ
No market on this figure
Q4 2026 reported
$568,000,000
+9.4% QoQ
Reported